



Cite this: DOI: 10.1039/c5bm00355e

Received 31st August 2015,
Accepted 10th November 2015

DOI: 10.1039/c5bm00355e

www.rsc.org/biomaterialsscience

Control of growth factor binding and release in bisphosphonate functionalized hydrogels guides rapid differentiation of precursor cells *in vitro*†

Sujit Kootala,^a Yu Zhang,^a Sara Ghalib,^a Vladimir Tolmachev,^b Jöns Hilborn^a and Dmitri A. Ossipov^{*a}

An *in situ* cross-linkable hyaluronan hydrogel functionalized with bisphosphonate (BP) groups allows tunable release of bone morphogenetic protein-2 (BMP-2) determined by the amount of BP groups. The high affinity of matrix-anchored BP groups towards BMP-2 permits guided differentiation of entrapped progenitor cells in 3-D cultures.

Growth factors are important signalling proteins that stimulate cell growth, differentiation, survival, inflammation, and tissue repair.^{1,2} Due to their short half-life and gradual diffusion into extracellular spaces, growth factors usually act swiftly and locally. Moreover, the binding ability of a growth factor to domains on extracellular matrices (ECM), degradation of ECM, and the overall concentration of the growth factor have pronounced effects on the actual response of a target cell.

Scaffold-assisted repair or replacement of damaged tissues often relies on the ability of a biomaterial to control the delivery of growth factors.³ However, retention of their bioactivity from the time of encapsulation in the biomaterial until the time of interaction with cells is a major challenge.⁴ *In vivo*, growth factor activity is controlled spatiotemporally by non-covalent interactions with sulphated proteoglycans or their glycosaminoglycan (GAG) subunits. Biomimetic approaches to growth factor delivery contemplate biomaterials as a growth factor depot in which stable and local presentation of the growth factor is realized by covalent linking or through specific physical interactions.⁵

A synthetic approach to current ECM mimics involves retro-synthetic deconstruction of ECM macromolecules into functional subunits (epitopes) and their re-assembly using an orthogonal combination of site-specific chemical reactions and/or affinity interactions. For example, site-specific immobilization of growth factors to fibrin^{6–8} or poly(ethylene glycol)⁹

involving a transglutaminase FXIIIa-mediated enzymatic reaction permitted unprecedented control over growth factor release determined exclusively by the proteolytic activity of invading cells. Alternatively, specific affinity interactions, which are engineered between the proteins and different matrices,¹⁰ tuned the rate of release while maintaining bio-activity. Synthetically, these systems include (i) chemical incorporation of a pair of complementary binding ligands to both a polymeric matrix and a therapeutic protein,^{11,12} (ii) modification of the therapeutic protein exclusively,¹³ and (iii) binding of parent growth factors to the matrix with the immobilized affinity ligand.^{14,15} However, all the delivery systems mentioned above, require time and labour-intensive modifications of either the growth factors (*via* genetic engineering, that might also compromise their activity) or matrices or both with expensive polypeptides. Heparin¹⁶ and heparin-mimetic¹⁷ systems represent the most exploited ligands that are naturally available, relatively easy to incorporate and bind native growth factors.¹⁸ However, some growth factors are non-binding or have variable binding to heparin, while others require specific sequences that are difficult to produce easily.^{19,20} Clearly, structurally simple affinity ligands that can provide enhanced retention of growth factors and can be easily incorporated *in situ* into a hydrogel-based delivery system that would allow preservation of their activity are highly desirable.

Previously, we reported the effect of bisphosphonate (BP) ligands attached to hyaluronic acid (HA) hydrogels to retain bone morphogenetic protein-2 (BMP-2) in the hydrazone cross-linked HABP matrix.²¹ Hyaluronic acid (HA) was used as a hydrogel-forming material due to its favourable characteristics as a biomaterial.²² Earlier studies demonstrated the suitability of HA for delivery of bone morphogenetic protein-2 (BMP-2) to trigger ectopic bone formation,²³ induce bone augmentation,²⁴ and for functional closure of bone defects.²⁵ Bisphosphonates (BPs) are well known anti-osteoporotic drugs that were also applied in bone regeneration by non-covalent incorporation into different scaffolds.²⁶ In the present work we have hypothesized that the binding properties of BPs can be successfully utilized in the fabrication of 3D cell cultures mimicking the


^aScience for Life Laboratory, Department of Chemistry-Ångström Laboratory, Uppsala University, Uppsala, Sweden. E-mail: dmitri.ossipov@kemi.uu.se

^bUnit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, S-75121 Uppsala, Sweden

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c5bm00355e

native features of ECM such as sequestration and storage of growth factors followed by their spatiotemporal release. Apart from using a different (disulfide) cross-linking chemistry, which was more suitable for 3D cell encapsulation, we varied the amount of BP groups in the matrix and demonstrated that in this way, one can tune binding of BMP-2 to the matrix which subsequently results in changing the rate of the growth factor release from the matrix. In this work, we also demonstrated for the first time that simultaneous *in situ* incorporation of BMP-2 and C2C12 myogenic progenitor cells in a HABP matrix can provide a stable osteogenic microenvironment for the cells (Fig. 1). Such an *in situ* cross-linkable hydrogel system thus promotes more efficient guiding of cells in 3D.

Entrapment of cells and BMP-2 in BP-functionalized hydrogels should be implemented *in situ*, i.e. cross-linking should be chemo-selective to ensure cytocompatibility. We have chosen a thiol-disulfide exchange reaction to cross-link HA chains because it proved to be the most cytocompatible for several different cell types *in vitro*.²⁷ To ensure quick setting time for the hydrogels, we prepared two HA derivatives, HA-SH-BP and HA-SSPy. The HA backbone in these derivatives was functionalized with thiol (–SH) and 2-dithiopyridyl (–SSPy) groups respectively to form a mixing-triggered disulphide hydrogel (Fig. 1). The preparation of HA-SSPy has been reported by us previously²⁸ and the details of its synthesis can be found in the ESI.† The synthesis of the HA derivative dually modified with thiol groups and BP ligands was realized in three steps (Scheme 1). First, 3% of HA disaccharide units were thiolated with a linker 1 according to a literature procedure to afford HA-SH.²⁹ The BP groups were subsequently attached to the sulfhydryl groups of HA-SH by the photochemically induced thiol–ene reaction.²⁸ On average, five BP groups ($n = 5$) were linked per sulfhydryl group according to NMR and elemental analysis. Finally, the obtained HA-BP derivative was again thiolated during the course of water-soluble carbodi-



Scheme 1 Synthesis of chemically "clickable" bisphosphonate-derivatized HA (HA-SH-BP).

imide-mediated coupling of 1 followed by one-pot treatment with a reducing agent. This afforded bisphosphonated hyaluronan with 6% *in situ* cross-linkable thiol groups.

After purification, the structure of HA-SH-BP was confirmed by NMR analysis. The ¹H-NMR spectrum of HA-SH-BP showed signals in the range between 2.9 and 2.5 ppm (Fig. 2) corresponding to the –COCH₂–CH₂S[CH₂–CHCO]– sequence of the attached chains of n repeating units ($n \approx 5$) each carrying a BP moiety. Characteristic methylene protons adjacent to the bridging carbon of the bisphosphonate residue (–CH₂C(OH)–(PO₃H₂)₂) were observed at 2.2 ppm. Comparison of integration of these methylene protons with the acetamido moiety of the




Fig. 1 *In situ* encapsulation of myotube forming cells and BMP-2 in hyaluronic acid hydrogel to induce 3D differentiation of the cells through the controlled retention and release of the growth factor by the matrix-linked bisphosphonate (BP) ligands.




Fig. 2 ¹H NMR spectrum of HA-SH-BP.

N-acetyl-D-glucosamine allowed us to approximately determine the degree of BP modification, which was close to 15% (3% of thiol groups to which 5 BP moieties were linked). Attachment of the BP groups was also confirmed by ^{31}P -NMR, which showed a characteristic peak at 18.9 ppm (Fig. S4†).

For evaluation, a control thiolated hyaluronan lacking BP groups (HA-SH) was also synthesized and the amount of thiol groups in both derivatives was kept the same (6%). Mixing of the new HA-SH-BP derivative or its HA-SH analogue with 2-dithiopyridyl derivatized HA (HA-SSPy) afforded hydrogels with disulfide cross-links in less than a minute. Equal volumes of 2% (w/v) solutions of each component in serum-free cell culture medium (pH 7) were used to ensure an equimolar ratio between the cross-linking functional groups (provided that the same degree of modification around 6% was achieved in all the derivatives). The hydrogels were set overnight and their mechanical properties were evaluated by rheology. We observed higher elastic moduli for HABP gels ($G' = 1256 \pm 72$ Pa) than for HA gels ($G' = 990 \pm 82$ Pa). This can be explained by the presence of Ca^{2+} ions in cell culture medium. As a result, in addition to disulfide chemical cross-linking of HA chains, BP- Ca^{2+} coordination bonds can be formed in HABP gels which thus counterbalance electrostatic repulsion of the BP groups.³⁰

The release of BMP-2 was investigated using ^{125}I labelled protein.³¹ Due to the instability of BMP-2 it is equally important to correlate the release of the protein from hydrogels and the biological activity of the released protein on the cells.³¹ We therefore conduct a preliminary screening of two different commercial sources of rhBMP-2, *i.e.* Wyeth and Peprtech, to ascertain the efficiency of labelling and to probe the activity of the resultant protein-adduct in cells. We were able to label both the BMPs with similar efficiencies. However, we noticed a loss of biological activity of labeled Wyeth™ BMP-2 over time, even though the *in vitro* release profiles were more distinctive for HABP and HA hydrogels (Fig. S4†) and no loss in the cell proliferation rate was observed (data not shown). BMP-2 from Peprtech™ when labeled, however, did not show significant loss in activity and therefore, we chose to use this protein in our further studies.

Previously, we observed sequestration of Wyeth™ BMP-2 in HABP hydrogels cross-linked through hydrazone chemistry.²¹ In this work, almost the same effect was observed for the release of Wyeth™ BMP-2 from the disulphide cross-linked HABP hydrogel (Fig. S5†). The Peprtech™ BMP-2 was not however sequestered in HABP hydrogels (green curve in Fig. 3) as it was observed with Wyeth™ BMP-2. Nevertheless, a distinctive binding affinity of BP groups toward Peprtech™ BMP-2 could still be detected upon varying the amount of these groups in the HA matrix. Our injectable hydrogel system allowed such variation through simple mixing of the pre-determined volumes of HA-SH-BP and HA-SH solutions. It allowed loading of equal quantities (0.1 mg mL^{-1}) of BMP-2 into hydrogel samples with variable amounts of HA-SH-BP component *in situ* by addition of the growth factor into HA-SSPy solution followed by addition of the thiolated counterpart. It




Fig. 3 Tunable *in vitro* release profile of ^{125}I -labelled BMP-2 (Peprtech™) (0.1 µg) from 2% (w/v) disulfide cross-linked HA hydrogels of 100 µL by volume and different contents of HA-SH-BP. 1000 µg, 1.96 µg, 0.84 µg, and 0 µg of HA-SH-BP loading correspond to green, blue, pink, and red release curves respectively.

was noteworthy that the change in the retention of Peprtech™ BMP-2 could be achieved in the range of [BP]/[BMP-2] molar ratios between 0 and 10 and corresponding to the amounts of HA-SH-BP varying from 0 to 2 µg (red, pink, and blue curves in Fig. 3). These amounts are 1000 times less than the total HA content in the hydrogel. It demonstrates that the BP groups have indeed very high affinity to the protein which can be effectively used for tuning the release of the protein from HA hydrogels. The smaller differences between the release curves as well as the relative retention of BMP-2 in the control HA hydrogels can be explained by the presence of different forms of iodinated BMP-2 including aggregates or radioactive impurities. This could impair the radioactivity read-out from the release study.

Next we evaluated the biological activity of BMP-2 measured as cell differentiation induced by culturing myogenic progenitor cells C2C12 inside the hydrogel materials. The C2C12 cells were chosen due to their innate ability to express the early stage bone marker, alkaline phosphatase (ALP), upon stimulation with BMP-2.¹⁸ The C2C12 cells were shown as a useful cell line to study bone markers in the presence of BMPs.³² First we confirmed that the cell survival was close to 100% upon *in situ* entrapment and further 3D culturing in the disulphide cross-linked HA and HABP hydrogels (Fig. S6†). The cells proliferated comparably over 7 days in both types of hydrogels irrespective of the presence or absence of the growth factor. Subsequently, approximately 30 000 cells were encapsulated in the hydrogels of 150 µL volume containing Peprtech™ BMP-2 at 1 µg mL^{-1} concentration. The expression of alkaline phosphatase (ALP), a major early-stage osteogenic differentiation marker, was measured. A 5-fold increase in ALP expression was detected for the cells cultured in 3D in HABP hydrogels as compared to HA hydrogels. It is noteworthy that culturing of the cells in HABP hydrogels without BMP-2




Fig. 4 Comparative *in vitro* ALP activity of C2C12 cells after culturing in hydrogels for 5 days.

did not result in the cells expressing ALP at all (Fig. 4). This observation is a direct consequence of the combined effect of matrix-linked BP groups and active BMP-2 on the cells. To ascertain the morphology and spreading of the cells after the induction period, the hydrogels were washed and stained with a CMFDA green dye. We found that the cells in the HABP gels containing BMP-2 showed spreading at day 5 (Fig. S7a†) while the cells did not spread in HA gels (Fig. S7b†). The anti-adhesive properties of HA are very well known. However, attachment of the BP groups may provide Ca^{2+} ion mediated interactions of membrane proteins with the BP groups of the matrix. The same effect was observed by us previously for 2D cultures on HABP hydrogels.²¹ Taking into account the results obtained from our release study, we can suggest that the cells were exposed to BMP-2 for a longer time and higher concentrations in the HABP hydrogel that acted as a pocket-like protective storage and supply for the growth factor in similarity to the native ECM. In addition to this, the products of degradation of HABP hydrogels are expected to have potent anti-osteoclastic activity as was shown by us recently.³³ On the contrary, HA hydrogels alone allowed less efficient protection and released BMP-2 too fast to provide local therapeutic doses for the cells during all five days of culturing and induced significant cell differentiation.

Acknowledgements

The research leading to these results has received funding from FP-7 European projects (BIODESIGN, 262948-2 and (MultiTERM grant no. 238551).

Notes and references

- 1 J. E. Babensee, L. V. McIntire and A. G. Mikos, Growth factor delivery for tissue engineering, *Pharmacol. Res.*, 2000, **17**, 497–504.

- 2 K. Unsicker, *Cell Signaling and Growth Factors in Development*, ed. K. Kriegstein, Wiley-VCH, Weinheim, Germany, 2006, vol. 1–2.
- 3 G. A. Hudalla and W. L. Murphy, Biomaterials that Regulate Growth Factor Activity via Bioinspired Interactions, *Adv. Funct. Mater.*, 2011, **21**, 1754–1768.
- 4 S. D. Putney and P. A. Burke, Improving protein therapeutics with sustained-release formulations, *Nat. Biotechnol.*, 1998, **16**, 153–157.
- 5 P. S. Lienemann, M. P. Lutolf and M. Ehrbar, Biomimetic hydrogels for controlled biomolecule delivery to augment bone regeneration, *Adv. Drug Delivery Rev.*, 2012, **64**, 1078–1089.
- 6 J. C. Schense and J. A. Hubbell, Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa, *Bioconjugate Chem.*, 1999, **10**, 75–81.
- 7 M. Ehrbar, V. G. Djonov, C. Schnell, S. A. Tschanz, G. Martiny-Baron, U. Schenk, J. Wood, P. H. Burri, J. A. Hubbell and A. H. Zisch, Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth, *Circ. Res.*, 2004, **94**, 1124–1132.
- 8 H. G. Schmoekel, F. E. Weber, J. C. Schense, K. W. Gratz, P. Schawalder and J. A. Hubbell, Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices, *Biotechnol. Bioeng.*, 2005, **89**, 253–262.
- 9 M. Ehrbar, S. C. Rizzi, R. G. Schoenmakers, B. S. Miguel, J. A. Hubbell, F. E. Weber and M. P. Lutolf, Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions, *Biomacromolecules*, 2007, **8**, 3000–3007.
- 10 K. Vulic and M. S. Shoichet, Affinity-based drug delivery systems for tissue repair and regeneration, *Biomacromolecules*, 2014, **15**, 3867–3880.
- 11 K. Vulic and M. S. Shoichet, Tunable growth factor delivery from injectable hydrogels for tissue engineering, *J. Am. Chem. Soc.*, 2012, **134**, 882–885.
- 12 R. Y. Tam, M. J. Cooke and M. S. Shoichet, *J. Mater. Chem.*, 2012, **22**, 19402–19411.
- 13 B. Chen, H. Lin, J. Wang, Y. Zhao, B. Wang, W. Zhao, W. Sun and J. Dai, Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2, *Biomaterials*, 2007, **28**, 1027–1035.
- 14 C. Lin and K. S. Anseth, Controlling Affinity Binding with Peptide-Functionalized Poly(ethylene glycol) Hydrogels, *Adv. Funct. Mater.*, 2009, **19**, 2325–2331.
- 15 N. A. Impellitteri, M. W. Toepke, S. K. L. Levensgood and W. L. Murphy, Specific VEGF sequestering and release using peptide-functionalized hydrogel microspheres, *Biomaterials*, 2012, **33**, 3475–3484.
- 16 Y. K. Joung, J. W. Bae and K. D. Park, Controlled release of heparin-binding growth factors using heparin-containing particulate systems for tissue regeneration, *Expert Opin. Drug Delivery*, 2008, **5**, 1173–1184.
- 17 B. P. Purcell, I. L. Kim, V. Chuo, T. Guenin, S. M. Dorsey and J. A. Burdick, Incorporation of sulfated hyaluronic acid

- macromers into degradable hydrogel scaffolds for sustained molecule delivery, *Biomater. Sci.*, 2014, **2**, 693–702.
- 18 G. Bhakta, B. Rai, Z. X. H. Lim, J. H. Hui, G. S. Stein, A. J. van Wijnen, V. Nurcombe, G. D. Prestwich and S. M. Cool, Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2, *Biomaterials*, 2012, **33**, 6113–6122.
 - 19 B. L. Farrugia, M. S. Lord, J. Melrose and J. M. Whitelock, Can we produce heparin/heparan sulfate biomimetics using “mother-nature” as the gold standard?, *Molecules*, 2015, **20**, 4254–4276.
 - 20 S. Kanzaki, T. Takahashi, T. Kanno, W. Ariyoshi, K. Shinmyozu, T. Tujisawa and T. Nishihara, Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor, *J. Cell. Physiol.*, 2008, **216**, 844–850.
 - 21 G. Hulsart-Billstrom, P. K. Yuen, R. Marsell, J. Hilborn, S. Larsson and D. Ossipov, Bisphosphonate-linked hyaluronic acid hydrogel sequesters and enzymatically releases active bone morphogenetic protein-2 for induction of osteogenic differentiation, *Biomacromolecules*, 2013, **14**, 3055–3063.
 - 22 J. A. Burdick and G. D. Prestwich, Hyaluronic acid hydrogels for biomedical applications, *Adv. Mater.*, 2011, **23**, H41–H56.
 - 23 K. Bergman, T. Engstrand, J. Hilborn, D. Ossipov, S. Piskounova and T. Bowden, Injectable cell-free template for bone-tissue formation, *J. Biomed. Mater. Res., Part A*, 2009, **91**, 1111–1118.
 - 24 E. Martinez-Sanz, D. A. Ossipov, J. Hilborn, S. Larsson, K. B. Jonsson and O. P. Varghese, Bone reservoir: Injectable hyaluronic acid hydrogel for minimal invasive bone augmentation, *J. Controlled Release*, 2011, **152**, 232–240.
 - 25 C. Docherty, K. Bergman, A. Skogh, M. Waern, S. Ekman, K. Hultenby, D. Ossipov, J. Hilborn, T. Bowden and T. Engstrand, Bone morphogenetic protein-2 delivered by hyaluronan-based hydrogel induces massive bone formation and healing of cranial defects in minipigs, *Plast. Reconstr. Surg.*, 2010, **125**, 1383–1392.
 - 26 J. P. Cattalini, A. R. Boccaccini, S. Lucangioli and V. Mourino, Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants, *Tissue Eng., Part B*, 2012, **18**, 323–340.
 - 27 S. Y. Choh, D. Cross and C. Wang, Facile synthesis and characterization of disulfide-cross-linked hyaluronic acid hydrogels for protein delivery and cell encapsulation, *Biomacromolecules*, 2011, **12**, 1126–1136.
 - 28 D. Ossipov, S. Kootala, Z. Yi and J. Hilborn, Orthogonal Chemoselective Assembly of Hyaluronic Acid Networks and Nanogels for Drug Delivery, *Macromolecules*, 2013, **46**, 4105–4113.
 - 29 X. Z. Shu, Y. Liu, Y. Luo, M. C. Roberts and G. D. Prestwich, Disulfide cross-linked hyaluronan hydrogels, *Biomacromolecules*, 2002, **3**, 1304–1311.
 - 30 M. R. Nejadnik, X. Yang, M. Bongio, H. S. Alghamdi, J. J. van den Beucken, M. C. Huysmans, J. A. Jansen, J. Hilborn, D. Ossipov and S. C. Leeuwenburgh, Self-healing hybrid nanocomposites consisting of bisphosphonated hyaluronan and calcium phosphate nanoparticles, *Biomaterials*, 2014, **35**, 6918–6929.
 - 31 S. Piskounova, L. Gedda, G. Hulsart-Billstrom, J. Hilborn and T. Bowden, Characterization of recombinant human bone morphogenetic protein-2 delivery from injectable hyaluronan-based hydrogels by means of ¹²⁵I-radiolabelling, *J. Tissue Eng. Regener. Med.*, 2014, **8**, 821–830.
 - 32 C. Rauch, A. C. Brunet, J. Deleule and E. Farge, C2C12 myoblast/osteoblast transdifferentiation steps enhanced by epigenetic inhibition of BMP2 endocytosis, *Am. J. Physiol.*, 2002, **283**, C235–C243.
 - 33 S. Kootala, D. Ossipov, J. J. P. van den Beucken, S. Leeuwenburgh and J. Hilborn, *Biomater. Sci.*, 2015, **3**, 1197–1207.